Phosphate salt of 1-((3s,4r)-3-((2-((1-ethyl-1h-pyrazol-4-yl)amino)-7h-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one, crystalline form thereof, and method for preparation thereof

HK40137483APending Publication Date: 2026-09-11DAEWOONG PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026126335
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-11-18
Filing Date
2026-07-17
Publication Date
2026-09-11

Smart Images

  • Figure 00000040_0000
    Figure 00000040_0000
  • Figure 00000042_0000
    Figure 00000042_0000
  • Figure 00000043_0000
    Figure 00000043_0000
Patent Text Reader

Abstract

The present disclosure relates to phosphates of 1-((3S, 4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl) amino)-7H-pyrrolo [2, 3-d] pyrimidin-4-yl) oxy)-4-fluoropiperidin-1-yl) prop-2-en-1-one, crystalline forms thereof, and processes for their preparation. The phosphates and crystalline forms have low hygroscopicity and improved stability and solubility compared to free bases, thereby being suitable for pharmaceutical use. In addition, the preparation method of the phosphate and the crystalline form according to the present disclosure has the following advantages: large-scale production is possible, and the safety of the preparation process is improved by using materials that are safer than reactants used in conventional preparation methods.
Need to check novelty before this filing date? Find Prior Art

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480077082.1 (22) Application Date 2024.12.05 (30) Priority Data 10-2023-0174736 2023.12.05 KR 10-2023-0174738 2023.12.05 KR 10-2024-0006933 2024.01.16 KR 10-2024-0164590 2024.11.18 KR (85) PCT International Application Entering National Phase Date 2026.06.04 (86) PCT International Application Application Data PCT / KR2024 / 019814 2024.12.05 (87) Publication data of PCT international application WO2025 / 121900 KO 2025.06.12 (71) Applicant Daewoong Pharmaceutical Co., Ltd. Address 35-14, 4-ga, Hyangnam-eup Pharmaceutical Industrial Park, Hwaseong-do, Gyeonggi-do, South Korea (72) Inventors Park Joon-seok, Hyun Hae-jung, Lee Sun-hwan, Jeon Seon-ah, Kim Nam-yoon, Kim Won-sun, Kim Cheol-woong (74) Patent Agency Beijing Patern Intellectual Property Agency Co., Ltd. 11270 Patent Attorney Zhao Guifang, Xu Chuan (51) Int.Cl. C07D 487 / 04 (2006.01) A61K 31 / 519 (2006.01) (54) Invention title 1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-D]pyrimidin-4-yl)oxy)- Phosphate of 4-fluoropiperidin-1-yl)prop-2-en-1-one, its crystalline form and preparation method thereof (57) Abstract This disclosure relates to the phosphate of 1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one, its crystalline form and preparation method thereof. The phosphate and crystalline form exhibit low hygroscopicity and improved stability and solubility compared to the free base, thus making them suitable for pharmaceutical applications. Furthermore, the preparation method of the phosphate and crystalline form according to this disclosure has the advantages of large-scale production and improved safety of the preparation process by using materials that are safer than those used in conventional preparation methods.Claims 5 pages, Description 21 pages, Drawings 4 pages, CN 122319150 A 2026.06.30 CN 1 22 31 91 50 A 1.1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)propyl-2-en-1-one phosphate. 2. The phosphate of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)propyl-2-en-1-one according to claim 1, wherein, in an X-ray powder diffraction pattern irradiated by a Cu light source, the phosphate has three or more peaks selected from the group consisting of: 3.9°, 7.8°, 8.5°, 9.2°, 10.0°, 10.2°, 12.8°, 14.4°, 15.8°, 16.0°, 20.8°, 21.2°, 21.6°, 22.3°, and 25.5° with diffraction angles (2θ ± 0.2°). 3. The phosphate of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)propyl-2-en-1-one according to claim 1, wherein, in differential scanning calorimetry analysis, the phosphate has an endothermic onset temperature of 106.52 ± 1.0 °C and exhibits a maximum endothermic peak at an endothermic temperature of 123.8 ± 1.0 °C.4. A method for preparing a phosphate of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one, the method comprising: (step 1) reacting a compound represented by chemical formula 1-1 with a compound represented by chemical formula 1-2 in the presence of a base to prepare a compound represented by chemical formula 1-3; (step 2) reacting a compound represented by chemical formula 1-3 with a compound represented by chemical formula 1-4 in the presence of a palladium catalyst and a base to prepare a compound represented by chemical formula 1-5; (step 3) reacting a compound represented by chemical formula 1-5 with an acid to prepare a compound represented by chemical formula 1-6; (Step 4) Reacting a compound represented by Chemical Formulas 1-6 with a compound represented by Chemical Formulas 1-7 in the presence of a base to prepare a compound represented by Chemical Formula 1; and (Step 5) Reacting a compound represented by Chemical Formula 1 with phosphoric acid to prepare a phosphate of the compound represented by Chemical Formula 1, wherein at least one of steps 1 to 4 further comprises a crystallization step: [Chemical Formula 1] [Chemical Formula 1-1] [Chemical Formula 1-2] Claims 1 / 5 Page 2 CN 122319150 A [Chemical Formula 1-3] [Chemical Formula 1-4] [Chemical Formula 1-5] [Chemical Formula 1-6] [Chemical Formula 1-7] Wherein in Chemical Formulas 1-1 to 1-7, P1 refers to a protecting group. 5. The preparation method according to claim 4, wherein in step 1, based on 1 equivalent of the compound represented by Chemical Formula 1-1, a compound represented by Chemical Formula 1-2 is used in an amount of 0.1 to 10 equivalents. 6. The preparation method according to claim 4, (Claims 2 / 5, page 3, CN 122319150 A) wherein, in step 1, the base is at least one selected from the group consisting of: potassium tert-butoxide, sodium tert-butoxide, potassium methoxide, sodium methoxide, potassium tert-pentoxide, sodium tert-pentoxide, triethylamine, diisopropylethylamine, sodium hydroxide, potassium hydroxide, lithium hydroxide, potassium carbonate, calcium carbonate, sodium carbonate, potassium bicarbonate, sodium bicarbonate, and cesium carbonate. 7. The preparation method according to claim 4, wherein, in step 1, the base is used in an amount of 0.1 to 10 equivalents based on 1 equivalent of the compound represented by formula 1-1.8. The preparation method according to claim 4, wherein, in step 1, the reaction is carried out in one or more organic solvents selected from the group consisting of: tetrahydrofuran (THF), 1,4-dioxane, methanol, ethanol, isopropanol, 1-butanol, 2-butanol, acetone, methyl ethyl ketone, ethyl acetate, methyl tert-butyl ether, acetonitrile, toluene, heptane, 3-methyltetrahydrofuran, dichloromethane, methyl isobutyl ketone, dimethylformamide (DMF), dimethylacetamide (DMAC), and dimethyl sulfoxide (DMSO). 9. The preparation method according to claim 8, wherein, in step 1, the reaction is carried out at 30 to 60°C. 10. The preparation method according to claim 4, wherein, after the compound represented by formula 1-1 reacts with the compound represented by formula 1-2 in the presence of a base, step 1 further comprises a step of crystallizing the reaction product. 11. The preparation method according to claim 4, wherein, in step 2, the compound represented by chemical formula 1-4 is used in an amount of 0.1 to 10 equivalents based on 1 equivalent of the compound represented by chemical formula 1-3. 12. The preparation method according to claim 4, wherein, in step 2, the palladium catalyst is at least one selected from the group consisting of: tris(dibenzylacetone)palladium(O), tetra(triphenylphosphine)palladium(O), bis[tris(2-methylphenyl)phosphine]palladium, palladium(II) acetate, 1,1-(bis(diphenylphosphine)ferrocene)palladium(II) chloride, and palladium(II) chloride. 13. The preparation method according to claim 4, wherein, in step 2, the base is at least one selected from the group consisting of: potassium tert-butoxide, sodium tert-butoxide, potassium methoxide, sodium methoxide, potassium tert-pentoxide, sodium tert-pentoxide, triethylamine, diisopropylethylamine, sodium hydroxide, potassium hydroxide, lithium hydroxide, potassium carbonate, calcium carbonate, sodium carbonate, potassium bicarbonate, sodium bicarbonate, and cesium carbonate. 14. The preparation method according to claim 4, wherein, in step 2, the reaction is carried out in one or more organic solvents selected from the group consisting of: tetrahydrofuran (THF), 1,4-dioxane, sec-butanol, methanol, ethanol, isopropanol, 1-butanol, 2-butanol, tert-butanol, acetone, methyl ethyl ketone, ethyl acetate, methyl tert-butyl ether, acetonitrile, toluene, xylene, heptane, 3-methyltetrahydrofuran, dichloromethane, methyl isobutyl ketone, dimethylformamide (DMF), dimethylacetamide (DMAC), and dimethyl sulfoxide (DMSO). 15. The preparation method according to claim 4, wherein the reaction in step 2 is carried out at 80 to 100°C.16. The preparation method according to claim 4, wherein, in step 3, the acid is at least one selected from the group consisting of: hydrochloric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, bromic acid, sulfuric acid, nitric acid, and iodic acid. 17. The preparation method according to claim 4, wherein, in step 3, the reaction is carried out in one or more organic solvents selected from the group consisting of: ethyl acetate, dichloromethane, butyl acetate, trichloromethane, methanol, ethanol, isopropanol, 1-butanol, 2-butanol, acetone, methyl ethyl ketone, methyl tert-butyl ether, acetonitrile, toluene, heptane, tetrahydrofuran, 3-methyltetrahydrofuran, 1,4-dioxane, methyl isobutyl ketone, dimethylformamide (DMF), dimethylacetamide (DMAC), and dimethyl sulfoxide (DMSO). 18. The preparation method according to claim 4, wherein the reaction in step 3 is carried out at 0°C to 50°C. 19. The preparation method according to claim 4, wherein, after reacting the compounds represented by chemical formulas 1-5 with an acid, step 3 further comprises a step of crystallizing the reaction product. 20. The preparation method according to claim 4, wherein, in step 4, based on 1 equivalent of the compounds represented by chemical formulas 1-6, the compounds represented by chemical formulas 1-7 are used in an amount of 0.1 to 10 equivalents. 21. The preparation method according to claim 4, wherein, in step 4, the base is at least one selected from the group consisting of: potassium carbonate, sodium hydroxide, lithium hydroxide, potassium hydroxide, triethylamine, diisopropylamine, diisopropylethylamine, sodium bicarbonate, potassium bicarbonate, cesium carbonate, sodium carbonate, sodium methoxide, and potassium butyrate. 22. The preparation method according to claim 4, wherein the reaction in step 4 is carried out at -10°C to 50°C. 23. The preparation method according to claim 4, wherein, after reacting the compounds represented by chemical formulas 1-6 with the compounds represented by chemical formulas 1-7 in the presence of a base, step 4 further comprises a step of crystallizing the reaction product. 24. The preparation method according to claim 4, wherein, in step 5, the reaction is carried out in one or more organic solvents selected from the group consisting of: 2-butanol, acetone, methyl ethyl ketone, ethyl acetate, methyl tert-butyl ether, acetonitrile, toluene, heptane, tetrahydrofuran, 3-methyltetrahydrofuran, 1,4-dioxane, dichloromethane, methyl isobutyl ketone, dimethylformamide (DMF), dimethylacetamide (DMAC), and dimethyl sulfoxide (DMSO).25. Crystalline form of phosphate of 1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)propyl-2-en-1-one. 26. The crystalline form of the phosphate of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)propyl-2-en-1-one according to claim 25, wherein, in an X-ray powder diffraction pattern, the crystalline form has three or more peaks selected from the group consisting of: 3.9°, 7.8°, 8.5°, 9.2°, 10.0°, 10.2°, 12.8°, 14.4°, 15.8°, 16.0°, 20.8°, 21.2°, 21.6°, 22.3°, and 25.5° with diffraction angles (2θ ± 0.2°). 27. The crystalline form of the phosphate of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one according to claim 25, wherein, in differential scanning calorimetry analysis, the crystalline form has an endothermic onset temperature of 106.52 ± 1.0 °C and exhibits a maximum endothermic peak at an endothermic temperature of 123.8 ± 1.0 °C. 28. A pharmaceutical composition for the prevention or treatment of inflammatory diseases, autoimmune diseases, proliferative diseases, hyperproliferative diseases, immune-mediated diseases, cancer, or tumors, the pharmaceutical composition comprising at least one of the following groups: 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one phosphate, and the crystalline form of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one phosphate. 29. A method for preparing a phosphate of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one, said method comprising a compound represented by the following chemical formulas 1-5 as an intermediate: [Chemical Formulas 1-5] wherein in Chemical Formulas 1-5, P1 refers to a protecting group.30. The preparation method according to claim 29, wherein P1 is tert-butoxycarbonyl (Boc). 31. A compound represented by the following chemical formulas 1-5, [chemical formulas 1-5] wherein, in chemical formulas 1-5, P1 refers to a protecting group. 32. The compound according to claim 31, wherein P1 is tert-butoxycarbonyl (Boc). Claims 5 / 5 Page 6 CN 122319150 A 1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-D]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one phosphate, its crystalline form and preparation method thereof Technical Field

[0001] Cross-reference to related applications This application claims Korean Patent Application No. 10-2023-0174736 filed on December 5, 2023, Korean Patent Application No. 10-2023-0174738 filed on December 5, 2023, Korean Patent Application No. 10-2024-0006933 filed on January 16, 2024, and Korean Patent Application No. 10- Priority and benefits of application 2024-0164590, the entire contents of which are incorporated herein by reference.

[0002] This disclosure relates to phosphates of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)propyl-2-en-1-one, their crystalline forms, and methods for their preparation. Background Art

[0003] The selection of pharmaceutically acceptable salts and their polymorphs is a crucial step in the research and development of new drugs. This is because certain salt forms and their polymorphs can significantly influence the development of pharmaceutical raw material production processes and the design and formulation of finished pharmaceutical products.

[0004] Specifically, the type of salt and its polymorph can affect the recrystallization yield, process rate, and purity in the final stages of pharmaceutical raw material production. In particular, the rate of crystallization can vary depending on the size or shape of the crystals; therefore, the selection of salts and polymorphs is also important from the perspective of pharmaceutical raw material productivity and production costs.

[0005] Furthermore, adding salts to certain drugs can be a means of altering the physicochemical and biological properties of the drug without modifying its chemical structure. This is because, in pharmaceuticals, the form of salts and their polymorphs affects physicochemical properties such as hygroscopicity, stability, solubility, particle flowability, and dissolution rate. Therefore, the form of salts and their polymorphs is a factor that determines the manufacturing process, production and storage conditions, shelf life, etc., of the finished pharmaceutical product.

[0006] Therefore, there is a need for ongoing research into the selection of salts and polymorphs that can exhibit better stability and bioavailability in the preparation of specific pharmaceutical formulations.

[0007] Meanwhile, the inventors have discovered that 1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)propyl-2-en-1-one, as a novel active pharmaceutical ingredient, exhibits excellent inhibitory activity as an inhibitor of both JAK3 and BTK kinases.

[0008] Therefore, the inventors have conducted in-depth research on pharmaceutically acceptable salts and the selection of their polymorphs that can improve the solubility and stability of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one, and have thus found that when prepared as a phosphate, the compound can be obtained as a crystalline structure and its solubility, crystallinity and stability under harsh conditions can be improved, thus completing this disclosure.

[0009] [Technical Problem] The object of this disclosure is to provide a phosphate of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one.

[0010] Another object of this disclosure is to provide a method for preparing a phosphate of 1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one.

[0011] Another object of this disclosure is to provide the crystalline form of the phosphate of 1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one.

[0012] Another object of this disclosure is to provide a pharmaceutical composition for the prevention or treatment of inflammatory diseases, autoimmune diseases, proliferative diseases, hyperproliferative diseases, immune-mediated diseases, cancer or tumors, the pharmaceutical composition comprising at least one selected from the group consisting of: phosphate of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one and phosphate of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one in crystalline form.

[0013] Another object of this disclosure is to provide a novel intermediate compound obtained in the preparation of phosphate of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one.

[0014] [Technical Solution] To achieve the above object, phosphate of 1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one is provided.

[0015] In addition, a method is provided for preparing a phosphate of 1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one (a compound represented by the following chemical formula 1).More specifically, the preparation method includes the following steps, wherein at least one of steps 1 to 4 further includes a crystallization step: (Step 1) reacting a compound represented by chemical formula 1-1 with a compound represented by chemical formula 1-2 in the presence of a base to prepare a compound represented by chemical formula 1-3; (Step 2) reacting a compound represented by chemical formula 1-3 with a compound represented by chemical formula 1-4 in the presence of a palladium catalyst and a base to prepare a compound represented by chemical formula 1-5; (Step 3) reacting a compound represented by chemical formula 1-5 with an acid to prepare a compound represented by chemical formula 1-6; (Step 4) reacting a compound represented by chemical formula 1-6 with a compound represented by chemical formula 1-7 in the presence of a base to prepare a compound represented by chemical formula 1; and (Step 5) reacting a compound represented by chemical formula 1 with phosphoric acid to prepare a phosphate of a compound represented by chemical formula 1: [Chemical Formula 1] Specification 2 / 21 Page 8 CN 122319150 A

[0016] [Chemical Formula 1-1]

[0017] [Chemical Formula 1-2]

[0018] [Chemical Formula 1-3]

[0019] [Chemical Formula 1-4]

[0020] [Chemical Formula 1-5]

[0021] [Chemical Formula 1-6] Specification 3 / 21 Page 9 CN 122319150 A

[0022] [Chemical Formula 1-7]

[0023] Wherein in chemical formulas 1-1 to 1-7, P1 refers to a protecting group.

[0024] This document further provides the crystalline form of the phosphate of 1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one.

[0025] Further, a method is provided for preparing a phosphate of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one, the method comprising a compound represented by the following chemical formulas 1-5 as an intermediate: [Chemical Formula 1-5]

[0026] wherein in chemical formula 1-5, P1 refers to a protecting group.

[0027] Further, a compound represented by the following chemical formulas 1-5 is provided: [Chemical Formula 1-5]

[0028] wherein in chemical formula 1-5, P1 refers to a protecting group.

[0029] Meanwhile, 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one is a novel active pharmaceutical material, represented by the following chemical formula 1: [Chemical Formula 1].

[0030] 1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one and its pharmaceutically acceptable salts may be advantageously used for the prevention or treatment of diseases to which kinase inhibition is effective. Therefore, 1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)propyl-2-en-1-one and its pharmaceutically acceptable salts may be useful for the prevention or treatment of inflammatory diseases, autoimmune diseases, proliferative diseases, hyperproliferative diseases, immune-mediated diseases, cancer, or tumors.

[0031] Wherein, the pharmaceutically acceptable salt of 1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one is the phosphate of 1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one. The phosphate can be prepared by reacting the free base of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one with phosphoric acid added in a specific ratio.

[0032] Furthermore, the phosphate of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one can be in crystalline form. Phosphates of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)propyl-2-en-1-one can be prepared by various crystallization methods, such as evaporation crystallization, extraction crystallization, reactive crystallization, solvent-mediated polymorphism, and solid-state polymorphism, which are selected based on the thermodynamic and kinetic properties of the salt.Therefore, the phosphate of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one can be prepared in its crystalline form.

[0033] The phosphate of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one or the crystalline form of the phosphate can be confirmed by X-ray powder diffraction analysis. Specifically, the phosphate or crystalline form can be distinguished by the diffraction angle (2θ) of the characteristic peaks displayed in the X-ray powder diffraction pattern and by the intensity of the peaks at each diffraction angle (2θ). Here, depending on various factors such as the production technology of the sample used for measurement, the procedure for fixing the sample used for measurement, and the measuring instrument, the diffraction angle (2θ) can have a difference of ±0.2°, or preferably ±0.1°.

[0034] Further, the phosphate of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one or the crystalline form of said phosphate can also be distinguished by the endothermic onset temperature and the endothermic temperature at which the maximum endothermic peak is displayed in differential scanning calorimetry analysis, respectively. Here, depending on various factors such as the production technology of the sample used for measurement, the measuring equipment, and the rate of temperature change, said temperature can have a difference of ±3°C, preferably ±2°C, or more preferably ±1°C.

[0035] The present disclosure will now be described in detail.

[0036] [1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one phosphate] It is known that the free base (free form) of 1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one has poor stability. Therefore, in order to improve the stability of these compounds, the inventors have conducted in-depth research on phosphoric acid and confirmed that when the compounds are combined with phosphoric acid in a specific equivalence ratio, their stability and crystallinity can be improved.

[0037] In the X-ray powder diffraction pattern irradiated by a Cu light source, the phosphate of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one can have three or more peaks selected from the group consisting of: 3.9°, 7.8°, 8.5°, 9.2°, 10.0°, 10.2°, 12.8°, 14.4°, 15.8°, 16.0°, 20.8°, 21.2°, 21.6°, 22.3°, and 25.5° (2θ ± 0.2°). Since the phosphate is prepared in both free base and crystalline forms, the X-ray powder diffraction pattern is observed.

[0038] Furthermore, in differential scanning calorimetry analysis, the phosphate of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one can have an endothermic onset temperature of 106.52±1.0 °C and show a maximum endothermic peak at an endothermic temperature of 123.8±1.0 °C.

[0039] Meanwhile, the phosphate of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one is prepared by the following reaction scheme 1: [Reaction Scheme 1]

[0040] Wherein in reaction scheme 1, P1 refers to a protecting group. Specification 6 / 21 page 12 CN 122319150 A

[0041] More specifically, P1 can be any protecting group selected from the group consisting of: tert-butoxycarbonyl (Boc), carbapenyloxy (Cbz), p-methoxybenzylcarbonyl (Moz), 9-fluorenylmethoxycarbonyl (Fmoc), acetyl (Ac), benzoyl (Bz), benzyl (Bn) and p-methoxybenzyl (PMB).

[0042] In this case, P1 is preferably tert-butyloxycarbonyl (Boc) in terms of ease of production and yield.

[0043] The preparation method does not involve substitution reactions of a separate protecting group, thus shortening the process steps compared to conventional preparation methods. The preparation method also does not involve a column purification step, thus improving the yield and / or purity of the final product. Furthermore, the preparation method involves crystallization purification in at least one or more steps, which is beneficial for large-scale production. In addition, the preparation method does not use previously used explosive strong bases (such as NaH), thereby ensuring safety during the process, and the reaction temperatures in some steps are lower than before, thus facilitating application in general production plants and having economic benefits.

[0044] Meanwhile, the various steps described below may further include a purification step after the reaction to prepare a compound with high purity and yield. In one example of the purification method, extraction utilizing solubility differences, adsorption using activated carbon and / or silica-based materials, filtration, precipitation, crystallization, etc., may be used. However, the purification method does not use column chromatography, which is not suitable for large-scale production. Preferably, the purification step may be performed as described in the various steps.

[0045] Furthermore, the various steps may further include a crystallization step using a crystallization solvent as a final step. If a purification step is performed, the crystallization step may be performed after the purification step; and if no purification step is performed, the crystallization step may be performed after the reaction. By further including the crystallization step, large-scale production can be achieved. The crystallization solvent may be used depending on the product of each step, but there are no particular limitations. Preferably, the crystallization step may be performed as described in the various steps.

[0046] (Step 1) Step 1 is a step of reacting a compound represented by chemical formula 1-1 with a compound represented by chemical formula 1-2 in the presence of a base to prepare a compound represented by chemical formula 1-3. The reaction is a nucleophilic aromatic substitution reaction, which is carried out in the presence of a base so that the added compound represented by chemical formula 1-2 becomes a nucleophile.

[0047] In step 1, based on 1 equivalent of the compound represented by chemical formula 1-1, the compound represented by chemical formula 1-2 may be used in amounts from 0.1 to 10 equivalents. Specifically, based on 1 equivalent of the compound represented by chemical formula 1-1, the compound represented by chemical formula 1-2 may be used in amounts from 0.2 to 5 equivalents, 0.3 to 3 equivalents, 0.5 to 2 equivalents, 0.7 to 1.5 equivalents, 1 to 1.5 equivalents, 1 to 1.3 equivalents, 1 to 1.05 equivalents, or 1.05 equivalents.

[0048] Further, in step 1, the base may be at least one selected from the group consisting of: potassium tert-butoxide, sodium tert-butoxide, potassium methoxide, sodium methoxide, potassium tert-pentoxide, sodium tert-pentoxide, triethylamine, diisopropylethylamine, sodium hydroxide, potassium hydroxide, lithium hydroxide, potassium carbonate, calcium carbonate, sodium carbonate, potassium bicarbonate, sodium bicarbonate, and cesium carbonate. Among these bases, potassium tert-butoxide is preferably used in terms of reaction rate and yield. It is sufficient that the base used is a non-explosive base to ensure safety, which is beneficial for industrialization.

[0049] Moreover, based on 1 equivalent of the compound represented by Formula 1-1, the base may be used in amounts from 0.1 to 10 equivalents. Preferably, based on 1 equivalent of the compound represented by Formula 1-1, the base may be used in amounts from 0.5 to 5 equivalents, 1 to 5 equivalents, 2 to 5 equivalents, 2 to 3 equivalents, or 3 equivalents. Using too little alkali risks prolonging the reaction time; and even using too much alkali does not result in a difference in reaction time, so it is preferable to use alkali within the above range.

[0050] In step 1, the reaction can be carried out in one or more organic solvents selected from the group consisting of: tetrahydrofuran (THF), 1,4-dioxane, methanol, ethanol, isopropanol, 1-butanol, 2-butanol, acetone, methyl ethyl ketone, ethyl acetate, methyl tert-butyl ether, acetonitrile, toluene, heptane, 3-methyltetrahydrofuran, dichloromethane, methyl isobutyl ketone, dimethylformamide (DMF), dimethylacetamide (DMAC), and dimethyl sulfoxide (DMSO). As an example, a solvent of type 1 (page 7 / 21 of CN 122319150 A) can be used, or a mixture of two or more types of solvents can be used. Preferably, 1,4-dioxane can be used as the organic solvent. The advantage of 1,4-dioxane is that it produces a higher purity product compared to other solvents and is easier to separate during extraction. The disadvantage of other solvents is that they produce relatively large amounts of impurities or have slow reaction rates.

[0051] Further, based on the weight of the compound represented by chemical formula 1-1, the organic solvent can be used in an amount of 5 to 30 times (mL / g), more specifically 5 to 15 times (mL / g).

[0052] Further, the reaction can be carried out at 30 to 60°C for 2 to 10 hours. If the reaction is carried out at a temperature below the above range and / or for a short reaction time, the reaction may not proceed sufficiently, which may result in a decrease in production yield. Furthermore, even if the reaction is carried out at a temperature above the above range and / or for a longer reaction time, the production yield will not substantially increase, which is undesirable in terms of process cost.

[0053] Meanwhile, after the reaction in step 1 is completed, the method may further include a purification step of extracting the reaction product using ethyl acetate and / or water. Specifically, ethyl acetate and water can be used to extract the reaction product. That is, after the reaction is completed, ethyl acetate and water can be used to extract the compound represented by chemical formula 1-3. Extraction using ethyl acetate and water can be carried out by stirring a mixture containing the reaction product and each solvent for 30 minutes or longer, allowing it to stand for 30 minutes or longer, and then separating the layers, discarding the aqueous layer (lower layer) and taking the organic layer (upper layer). Extraction using ethyl acetate and water can be repeated once or multiple times. In this extraction case, compared to extraction using a dichloromethane / water mixed solvent, impurities with relative retention times less than 1.0 separated by high-performance liquid chromatography (HPLC) can be effectively removed through the aqueous layer.

[0054] Furthermore, step 1 may further include filtering the extracted mixture and then performing vacuum concentration and / or azeotropic concentration. The vacuum concentration and / or azeotropic concentration steps are preferably performed after the extraction step with ethyl acetate and / or water.

[0055] Furthermore, step 1 may further include a step of crystallizing the reaction product to purify the compounds represented by chemical formulas 1-3. This crystallization step is preferably performed after the extraction and purification steps. In other words, step 1 can be performed by adding a crystallization solvent to the concentrated product after the extraction and purification steps and stirring at a temperature of about 20 to 50°C for 30 minutes to 4 hours to prepare the compounds represented by chemical formulas 1-3.

[0056] When the reaction product is prepared by crystallization in this manner, unlike column chromatography using silica columns for purification, it can be applied industrially, which is advantageous for large-scale industrial production and has the advantage of achieving high yields.

[0057] Specifically, the crystallization step can be performed by crystallization using water as the crystallization solvent. The crystallization step can be performed by repeating the crystallization process once or multiple times, in the order of adding the crystallization solvent and then stirring. In this way, when the crystallization process is repeated with multiple additions of solvent instead of a single addition, crystals adhering to the wall surface during solvent addition can be obtained, thereby preventing yield reduction, effectively removing residual byproducts after the reaction, and crystallizing uncrystallized products through repeated crystallization processes. Thus, compared to purification processes using solvents such as ethyl acetate in slurry form, high-purity compounds can be obtained in high yields.

[0058] The crystallization solvent used in a crystallization process can be used in an amount of 3 to 20 times the volume (mL / g), more specifically, in an amount of 3 to 10 times the volume (mL / g), relative to the weight of the compound represented by chemical formula 1-1.

[0059] A crystallization process can be carried out by stirring for 10 minutes to 2 hours at a temperature range of 5 to 30°C, preferably at room temperature (20 to 25°C). The time of the process can be adjusted appropriately; for example, the time of the process can be increased when the number of repetitions of the crystallization process is small, and decreased when the number of repetitions is large.

[0060] That is, when performing all the steps of purifying and crystallizing the reaction product in step 1 to prepare the compound represented by chemical formula 1-3 (page 8 / 21, CN 122319150 A), step 1 may include, but is not limited to, the following steps: reacting the compound represented by chemical formula 1-1 with the compound represented by chemical formula 1-2 in the presence of a base; adding ethyl acetate and water to discard the aqueous layer (lower layer) and separate and extract the organic layer (upper layer); and concentrating the purified mixture under vacuum and / or azeotropically; and crystallizing the concentrate.

[0061] After purifying the compound represented by chemical formula 1-3, the compound may be dried at 40 to 60°C for 10 to 14 hours to reduce the water content contained in the compound represented by chemical formula 1-3.More specifically, if the moisture content of the compounds represented by chemical formulas 1-3 is significantly reduced by drying at 50 to 60 °C, the conversion rate of the next step (i.e., step 2) can be increased.

[0062] (Steps 2 and 3) Step 2 is a step of reacting the compounds represented by chemical formulas 1-3 and 1-4 in the presence of a palladium catalyst and a base to prepare the compound represented by chemical formula 1-5, wherein a Buchwald-Hartwig amination reaction is carried out. The Buchwald-Hartwig amination reaction is a reaction that forms carbon and nitrogen bonds through a palladium-catalyzed coupling reaction of an amine with an aryl halide. Furthermore, Step 3 is a step of reacting the compounds represented by chemical formulas 1-5 with an acid to prepare the compound represented by chemical formula 1-6, which is a step for removing the protecting group P1 contained in chemical formulas 1-5.

[0063] The concentrated residual liquid containing compounds represented by chemical formulas 1-5 generated in step 2 can be used as is in the next step without a separate purification process to ensure a stable reaction without reducing yield or purity. Therefore, considering the economic benefits of omitting the purification step and the ease and convenience of the process, the concentrated residual liquid from step 2 can be used as is to prepare steps 2 and 3 in situ.

[0064] In step 2, based on 1 equivalent of the compounds represented by chemical formulas 1-3, compounds represented by chemical formulas 1-4 can be used in amounts of 0.1 to 10 equivalents. Specifically, based on 1 equivalent of the compounds represented by chemical formulas 1-3, compounds represented by chemical formulas 1-4 can be used in amounts of 0.2 to 5 equivalents, 0.5 to 5 equivalents, 0.5 to 3 equivalents, 0.5 to 2 equivalents, 0.5 to 1.5 equivalents, 1 to 1.5 equivalents, or 1.5 equivalents.

[0065] In step 2, the palladium catalyst may be a palladium (0) catalyst in which the valence of palladium (Pd) in the compound is 0, or a palladium (II) catalyst in which the valence is +2. For example, the palladium catalyst may be at least one selected from the group consisting of: tris(dibenzylacetone)palladium (0), tetra(triphenylphosphine)palladium (0), bis[tris(2-methylphenyl)phosphine]palladium, palladium (II) acetate, 1,1-(bis(diphenylphosphino)ferrocene)palladium (II) chloride, and palladium (II) chloride.

[0066] Further, in step 2, the base may be at least one selected from the group consisting of: potassium tert-butoxide, sodium tert-butoxide, potassium methoxide, sodium methoxide, potassium tert-pentoxide, sodium tert-pentoxide, triethylamine, diisopropylethylamine, sodium hydroxide, potassium hydroxide, lithium hydroxide, potassium carbonate, calcium carbonate, sodium carbonate, potassium bicarbonate, sodium bicarbonate, and cesium carbonate. The alkali used only needs to be a non-explosive alkali to ensure safety, which is beneficial for industrialization.

[0067] Furthermore, the reaction can be carried out in the presence of a phosphine-based compound, a palladium catalyst, and an alkali.As a phosphine-based compound, at least one selected from the group consisting of: 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl, 4,5-bis(diphenylphosphino)-9,9-dimethyloxanthracene, 2-(dicyclohexylphosphino)-3,6-dimethoxy-2,4'6'-triisopropyl-1,1'-biphenyl, 2-di-tert-butylphosphino-2',4',6'-triisopropylbiphenyl, and dicyclohexylphosphino-2',6'-diisopropoxybiphenyl.

[0068] Preferably, in step 2, based on 1 equivalent of the compound represented by chemical formulas 1-3, a base can be used in an amount of 0.1 to 10 equivalents as specified in the specification, page 9 / 21, 15 CN 122319150 A. Preferably, based on 1 equivalent of the compound represented by chemical formulas 1-3, the base can be used in amounts of 0.5 to 5 equivalents, 1 to 5 equivalents, 2 to 5 equivalents, 3 to 5 equivalents, or 3 equivalents. If too little base is used, there is a risk of prolonging the reaction time; and even if too much base is used, there is no difference in reaction time, so it is preferred to use base within the above range.

[0069] As the reaction solvent in step 2, a solvent inactive to the amine substitution reaction can be used. For example, the reaction can be carried out in one or more organic solvents selected from the group consisting of: tetrahydrofuran (THF), 1,4-dioxane, sec-butanol, methanol, ethanol, isopropanol, 1-butanol, 2-butanol, tert-butanol, acetone, methyl ethyl ketone, ethyl acetate, methyl tert-butyl ether, acetonitrile, toluene, xylene, heptane, 3-methyltetrahydrofuran, dichloromethane, methyl isobutyl ketone, dimethylformamide (DMF), dimethylacetamide (DMAC), and dimethyl sulfoxide (DMSO). For example, one type of solvent may be used, or a mixture of two or more types of solvents may be used, but sec-butanol is preferred in terms of reaction rate and yield.

[0070] The organic solvent may be used in an amount of 0.5 to 10 times the volume (mL / g), specifically 4 to 8 times, or 4 to 6 times the volume (mL / g), relative to the weight of the compound represented by chemical formulas 1-3. If the solvent is in excess during the reaction in step 2, there is a problem that the reaction may not proceed.

[0071] Further, the reaction may be carried out at a temperature of 80 to 100°C for 1 to 10 hours. If the reaction is carried out at a temperature below the above range and / or for a short reaction time, the reaction may not proceed sufficiently, which may result in a decrease in production yield. Furthermore, even if the reaction is carried out at a temperature above the above range and / or for a long reaction time, the production yield does not increase substantially, which is not preferred in terms of process cost. More specifically, the reaction can be carried out at a temperature of 85 to 95 °C or 88 to 92 °C for 1 to 6 hours, 1 to 4 hours, preferably 1 to 3 hours, and more preferably 1.5 to 2 hours.The reaction temperature is in a range far below the boiling point of the reaction solvent, which is significantly lower than the conventional reaction temperature, thus making it easy to apply in the process and reducing time and cost.

[0072] Further, when using the above-described combination of palladium catalyst, base, and phosphine-based compound, the reaction can be carried out in a known reactor. Thus, step 2 can be applied as a step in the process for large-scale production of the compound represented by formula 1.

[0073] Meanwhile, after the reaction in step 2 is completed, the method may further include a purification step of extracting the reaction product using ethyl acetate and water or using an aqueous solution of ethyl acetate and sodium chloride. Specifically, the reaction product can be extracted using ethyl acetate and water, or using an aqueous solution of ethyl acetate and sodium chloride, or using both of the above methods. That is, after the reaction is completed, the compound represented by formulas 1-5 can be extracted using ethyl acetate and water or using an aqueous solution of ethyl acetate and sodium chloride. Extraction using ethyl acetate and water or using an aqueous solution of ethyl acetate and sodium chloride can be carried out by stirring the mixture containing the reaction product and each solvent for 30 minutes or longer, allowing it to stand for 30 minutes or longer, and then separating the layers, discarding the aqueous layer (lower layer) and taking the organic layer (upper layer). Extraction using ethyl acetate and water can be repeated once or multiple times. In this case of extraction, compared to extraction using a dichloromethane / water mixed solvent, impurities with a relative retention time of less than 1.0 separated by high performance liquid chromatography (HPLC) can be effectively removed through the aqueous layer.

[0074] Further, step 2 may further include a step of vacuum concentration and / or azeotropic concentration of the extracted mixture. The vacuum concentration and / or azeotropic concentration step is preferably carried out after the extraction step with an aqueous solution of ethyl acetate and water or ethyl acetate and sodium chloride.

[0075] That is, when all the steps of purifying the reaction product in step 2 are performed to prepare the compound represented by chemical formulas 1-5, step 2 may include, but is not limited to, the following steps: reacting the compound represented by chemical formulas 1-3 with the compound represented by chemical formulas 1-4 in the presence of a palladium catalyst and a base; adding ethyl acetate and water or adding an aqueous solution of ethyl acetate and sodium chloride to discard the aqueous layer (lower layer) and separate and extract the organic layer (upper layer); and vacuum concentrating and / or azeotropically concentrating the purified mixture.

[0076] Meanwhile, after the reaction is complete, the processes of step 2 and step 3 described below can be carried out in situ in the same reaction vessel without the need for purification or separation of the compound represented by chemical formulas 1-5. In this way, since the purification and separation of the compound in step 2 is not required, the method for preparing the compound represented by chemical formula 1, including step 2, may be advantageous for the large-scale industrial production of the compound.

[0077] Step 3 is a step of reacting the compounds represented by chemical formulas 1-5 with an acid to prepare the compounds represented by chemical formulas 1-6, which is a step of removing the protecting group P1 contained in chemical formulas 1-5.

[0078] As the acid used in the reaction of step 3, at least one selected from the group consisting of: hydrochloric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, bromic acid, sulfuric acid, nitric acid, and iodic acid can be used. Among these acids, hydrochloric acid is preferred when considering yield and cost. Here, concentrated hydrochloric acid (c-HCl) can be used as hydrochloric acid. For example, concentrated hydrochloric acid with a concentration of about 30 to 40 wt.% can be used.

[0079] The acid can be used in an amount of 1 to 10 times the volume (mL / g) relative to the weight of the compounds represented by chemical formulas 1-5, more specifically in an amount of 2 to 5 times the volume (mL / g).

[0080] The reaction solvent in step 3 may be one or more organic solvents selected from the group consisting of: ethyl acetate, dichloromethane, butyl acetate, chloroform, methanol, ethanol, isopropanol, 1-butanol, 2-butanol, acetone, methyl ethyl ketone, methyl tert-butyl ether, acetonitrile, toluene, heptane, tetrahydrofuran, 3-methyltetrahydrofuran, 1,4-dioxane, methyl isobutyl ketone, dimethylformamide (DMF), dimethylacetamide (DMAC), and dimethyl sulfoxide (DMSO). As an example, one type of solvent may be used, or a mixture of two or more types of solvents may be used.

[0081] The organic solvent may be used in an amount of 5 to 30 times the volume (mL / g), more specifically 5 to 15 times, or 5 to 6 times the volume (mL / g), relative to the weight of the compound represented by formulas 1-5.

[0082] Further, the reaction can be carried out at 0°C to 50°C for 1 hour to 10 hours, preferably 3 hours to 5 hours. The removal reaction of the tert-butoxycarbonyl group (which is a protecting group) corresponds to a reaction that can be easily carried out without additional heat treatment and can be carried out within the above temperature range. However, if the reaction time is less than 1 hour, the reaction may not proceed sufficiently; if the reaction time exceeds 10 hours, the production yield will not increase substantially, so the above reaction time is preferred.

[0083] Meanwhile, after the reaction in step 3 is completed, the method may further include a purification step of extracting the reaction product. Preferably, there is no limitation on the solvent used for extraction, but as an example, the extraction step may use dichloromethane and water or ethyl acetate and water to extract the reaction product. That is, after the reaction is completed, the compound represented by chemical formulas 1-6 may be extracted using dichloromethane and water or ethyl acetate and water or both of the above methods.

[0084] Extraction using dichloromethane and water can be carried out by stirring a mixture containing the reaction product and each solvent for 30 minutes or longer, allowing it to stand for 30 minutes or longer, and then separating the layers, thereby discarding the organic layer (lower layer) and taking the aqueous layer (upper layer). Extraction using ethyl acetate and water can be carried out by stirring a mixture containing the reaction product and each solvent for 30 minutes or longer, allowing it to stand for 30 minutes or longer, and then separating the layers, thereby discarding the organic layer (lower layer) and taking the aqueous layer (upper layer). Extraction using dichloromethane and water or extraction using ethyl acetate and water can be repeated once or multiple times. Meanwhile, extraction using ethyl acetate and water is preferably carried out in the presence of a base such as sodium hydroxide, while maintaining the pH of the reaction product between 9 and 11.

[0085] Furthermore, step 3 may further include the step of vacuum concentration and / or azeotropic concentration of the extracted mixture. The vacuum concentration and / or azeotropic concentration steps are preferably performed after extraction with dichloromethane and water, or ethyl acetate and water, as described on page 11 / 21 of the specification, CN 122319150 A.

[0086] Moreover, step 3 may further include a step of crystallizing the reaction product to purify the compounds represented by chemical formulas 1-6. This crystallization step is preferably performed after the extraction and purification step. In other words, step 3 can be performed by adding a crystallization solvent to the concentrated product after the extraction and purification step and stirring the mixture at a temperature of about 20 to 40°C for 30 minutes to 4 hours to prepare the compounds represented by chemical formulas 1-6. Preferably, the crystallization step can be performed at room temperature of 20 to 30°C or 20 to 25°C.

[0087] In this way, when the reaction product is prepared by crystallization using a crystallization solvent, unlike the case of purification using a silica column, it can be applied to industrial applications, which is advantageous for large-scale industrial production and has the advantage of being able to obtain high yields.

[0088] Specifically, the crystallization step can be performed using methyl isobutyl ketone or n-heptane as a crystallization solvent. The order in which these two solvents are used is not limited, but it is preferred to proceed with the crystallization process using methyl isobutyl ketone followed by the crystallization process using n-heptane. The crystallization step can be performed by repeating the crystallization process once or multiple times, in the order of adding the crystallization solvent and then stirring. In this way, when the crystallization process is repeated while adding the solvent multiple times rather than all at once, crystals that adhere to the wall surface during solvent addition can even be obtained, thereby preventing yield reduction and effectively removing residual byproducts after the reaction. Furthermore, repeating the crystallization process can crystallize uncrystallized products. Thus, compared to purification processes using solvents such as ethyl acetate in slurry form, high-purity compounds can be obtained in high yields.

[0089] The crystallization solvent used in a crystallization process can be used in an amount of 3 to 20 times the volume (mL / g), more specifically, in an amount of 3 to 15 times the volume (mL / g), relative to the weight of the compound represented by chemical formulas 1-5. A crystallization process can be carried out by stirring for 10 minutes to 3 hours in a temperature range of 5 to 30°C. The time of the process can be adjusted appropriately, for example, increasing the time of the process when the number of repetitions of the crystallization process is small, and decreasing the time of the process when the number of repetitions is large.

[0090] That is, when performing all the steps of purifying and crystallizing the reaction product in step 3 to prepare the compound represented by chemical formulas 1-6, step 3 may include, but is not limited to, the following steps: reacting the compound represented by chemical formulas 1-5 with an acid; adding water and dichloromethane to discard the organic layer (lower layer) and separating and extracting the aqueous layer (upper layer); adding water and ethyl acetate to discard the aqueous layer (lower layer) and separating the organic layer (upper layer); and concentrating the purified mixture under vacuum and / or azeotropically; and crystallizing the concentrate.

[0091] After crystallizing and purifying the compound represented by chemical formulas 1-6, the compound may be dried at 30 to 60°C for 10 to 14 hours to reduce the water content contained in the compound represented by chemical formulas 1-6. More specifically, if the water content of the compound represented by chemical formulas 1-6 can be significantly reduced by drying at 50°C or lower, the conversion rate of the next step (i.e., step 4) can be increased.

[0092] (Step 4) Step 4 is an acrylic acidification reaction step, wherein the compound represented by chemical formulas 1-6 is reacted with the compound represented by chemical formulas 1-7 in the presence of a base to prepare the compound represented by chemical formula 1.

[0093] In step 4, based on 1 equivalent of the compound represented by chemical formulas 1-6, the compound represented by chemical formulas 1-7 can be used in amounts from 0.1 to 10 equivalents. Specifically, based on 1 equivalent of the compound represented by chemical formulas 1-6, the compound represented by chemical formulas 1-7 can be used in amounts from 0.2 to 5 equivalents, 0.5 to 5 equivalents, 0.5 to 3 equivalents, 0.5 to 2 equivalents, 0.5 to 1.5 equivalents, 1 to 1.5 equivalents, 1 to 1.1 equivalents, or 1.1 equivalents as specified on page 12 / 21 of the specification, CN 122319150 A.

[0094] As the base used in the reaction of step 4, at least one selected from the group consisting of: potassium carbonate, sodium hydroxide, lithium hydroxide, potassium hydroxide, triethylamine, diisopropylamine, diisopropylethylamine, sodium bicarbonate, potassium bicarbonate, cesium carbonate, sodium carbonate, sodium methoxide, and potassium butyrate. Among these bases, potassium carbonate, sodium carbonate, sodium bicarbonate, or potassium bicarbonate is preferred in terms of the degree of completion of the reaction and the formation of byproducts.

[0095] A mixed solvent of tetrahydrofuran (THF) and water can be used as the solvent for this reaction. In this case, tetrahydrofuran can be used at a volume (mL / g) of 5 to 40 times or 5 to 10 times the weight of the compounds represented by chemical formulas 1-6, and water can be used at a volume (mL / g) of 2 to 10 times or 2 to 5 times the weight.

[0096] Furthermore, the reaction in step 4 can be carried out at a temperature of -10°C to 50°C for 1 to 5 hours. Preferably, the reaction can be carried out at a temperature of 0°C or higher, more preferably at a temperature of 0°C or higher and 10°C or lower. Therefore, it is preferable to cool all reaction reagents, such as reactants and organic solvents, used to suppress the rise in reaction temperature during the reaction process to a temperature of 0°C or lower before use.

[0097] Meanwhile, after the reaction in step 4 is completed, the method may further include a purification step of extracting the reaction product. Specifically, ethyl acetate and water can be used to extract the reaction product. That is, after the reaction is complete, the compound represented by Formula 1 can be extracted using ethyl acetate and water. Extraction using ethyl acetate and water can be carried out by stirring a mixture containing the reaction product and each solvent for 30 minutes or longer, allowing it to stand for 30 minutes or longer, and then separating the layers, discarding the aqueous layer (lower layer) and using the organic layer (upper layer). In this extraction case, compared to extraction using a dichloromethane / water mixed solvent, impurities with a relative retention time of less than 1.0, separated by high-performance liquid chromatography (HPLC), can be effectively removed to the aqueous layer. Furthermore, if necessary, a purification process can be carried out using activated carbon and / or silica-based materials to remove byproducts or foreign substances.

[0098] Furthermore, step 4 may further include filtering the organic layer containing the extracted mixture and then concentrating it under vacuum. This vacuum concentration step is preferably carried out after the extraction step using ethyl acetate and / or water.

[0099] Preferably, step 4 may further include a step of crystallizing the reaction product to purify the compound represented by Formula 1. The crystallization step is preferably carried out after the extraction, purification, and vacuum concentration steps. In other words, step 4 can be carried out by adding a crystallization solvent to the concentrated product after the extraction and purification step and stirring at a temperature of about 20 to 40°C for 30 minutes to 4 hours. Preferably, the crystallization step can be carried out at room temperature of 20 to 30°C or 20 to 25°C. The time of this process can be appropriately adjusted by increasing the time of the process when the number of repetitions of the crystallization process is small, and decreasing the time of the process when the number of repetitions is large.

[0100] When the reaction product is prepared by crystallization using a crystallization solvent in this way, unlike the case of purification using a silica column, it can be applied to industrial applications, which is advantageous for large-scale industrial production and has the advantage of being able to obtain high yields.

[0101] Specifically, the crystallization step can be carried out by using ethanol or n-heptane as a crystallization solvent. There is no restriction on the order in which these two solvents are used. The crystallization step can be carried out by repeating the crystallization process once or multiple times, in the order of adding the crystallization solvent and then stirring. In this way, when the crystallization process is repeated while adding the solvent multiple times rather than all at once, crystals that adhere to the wall surface during the solvent addition process can even be obtained, thereby preventing a decrease in yield and effectively removing residual byproducts after the reaction. Furthermore, repeating the crystallization process can crystallize uncrystallized products. Thus, compared to purification processes using solvents in slurry form, high-purity compounds can be obtained in high yields.

[0102] The crystallization solvent can be used in an amount of 0.5 to 15 times the volume (mL / g) relative to the weight of the compound represented by chemical formulas 1-6, more specifically 0.5 to 10 times the volume (mL / g) of the solvent. A crystallization process can be carried out by stirring for 10 minutes to 2 hours at a temperature range of 5 to 30°C, preferably at room temperature (20 to 25°C). The time of the process can be adjusted appropriately; for example, the time of the process can be increased when the number of repetitions of the crystallization process is small, and the time of the process can be decreased when the number of repetitions is large.

[0103] Meanwhile, in order to crystallize more quickly, crystals of the compound represented by chemical formula 1 (which is a reaction product) can be added as seeds along with the solvent once or multiple times during the crystallization process. Based on 1 part by weight of the compound represented by chemical formulas 1-6, the seeds can be added in an amount of 0.01 parts by weight or less.

[0104] That is, when all the steps of purifying and crystallizing the reaction product in step 4 are performed sequentially to prepare the compound represented by chemical formula 1, step 4 may include, but is not limited to, the following steps: reacting the compounds represented by chemical formulas 1-6 with the compounds represented by chemical formulas 1-7 in the presence of a base; adding ethyl acetate and water to discard the aqueous layer (lower layer) and separating and extracting the organic layer (upper layer); and concentrating the purified mixture under vacuum; and crystallizing the concentrate.

[0105] After crystallization of the compound represented by chemical formula 1, the compound may be dried at 30 to 60°C for 8 to 14 hours to reduce the water content in the compound represented by chemical formula 1. More specifically, the compound may be dried at 50°C or lower.

[0106] (Step 5) Step 5 is the step of reacting the compound represented by Formula 1 with phosphoric acid to prepare the phosphate of 1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one.

[0107] Specifically, this step can be carried out according to a preparation method including the following steps:

[0108] 5-1) Dissolving 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one in an organic solvent; 5-2) Mixing phosphoric acid with the solution and stirring the mixture.

[0109] Step 5-2 is the step of preparing a salt in which 1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one is chemically bonded to phosphoric acid. The salt of 1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one chemically bonded to phosphoric acid may have a crystalline structure.

[0110] In the reaction, one or more organic solvents selected from the group consisting of: methanol, ethanol, isopropanol, 1-butanol, 2-butanol, acetone, methyl ethyl ketone, ethyl acetate, methyl tert-butyl ether, acetonitrile, toluene, heptane, tetrahydrofuran, 3-methyltetrahydrofuran, 1,4-dioxane, dichloromethane, methyl isobutyl ketone, dimethylformamide (DMF), dimethylacetamide (DMAC), and dimethyl sulfoxide (DMSO). The organic solvent can be used in amounts of 5 to 60 times the volume (mL / g) relative to the weight of the free base of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one. Preferably, the organic solvent can be used in amounts of 10 to 40 times the volume (mL / g) relative to the weight of the free base of 1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one.

[0111] In step 5, phosphoric acid may be used in an amount of 0.8 to 1.2 equivalents, preferably 1.0 to 1.2 equivalents, based on 1 equivalent of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one.

[0112] Next, the step of stirring a mixed solution of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one, phosphoric acid, and an organic solvent can be carried out at a temperature of 50°C to 70°C for 30 minutes to 30 hours.

[0113] The phosphate of 1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one prepared by the above preparation method can be recovered from the solution by a vacuum filtration process. If necessary, the recovered phosphate can be washed and vacuum dried to obtain a phosphate with high purity. Furthermore, the reaction conditions described in the above preparation method, such as the solvent ratio, temperature range, and process time, can be adjusted according to the selected solvent.

[0114] [Crystal form of phosphate of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one] In X-ray powder diffraction patterns, the crystalline form of phosphate of 1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one may have three or more peaks selected from the group consisting of: 3.9°, 7.8°, 8.5°, 9.2°, 10.0°, Diffraction angles of 10.2°, 12.8°, 14.4°, 15.8°, 16.0°, 20.8°, 21.2°, 21.6°, 22.3° and 25.5° (2θ ± 0.2°).

[0115] Further, in differential scanning calorimetry analysis, the crystalline form of the phosphate of 1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)propyl-2-en-1-one can have an endothermic onset temperature of 106.52 ± 1.0 °C and show a maximum endothermic peak at an endothermic temperature of 123.8 ± 1.0 °C.

[0116] When using the crystalline form of phosphates of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one or phosphates of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one, pK and solubility are improved compared to the case where the free base is used, and the stability is excellent.

[0117] Meanwhile, this disclosure provides a pharmaceutical composition comprising at least one selected from the group consisting of: phosphate of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one, and crystalline form of phosphate of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one.

[0118] More specifically, this disclosure provides a pharmaceutical composition for the prevention or treatment of inflammatory diseases, autoimmune diseases, proliferative diseases, hyperproliferative diseases, immune-mediated diseases, cancer, or tumors, the pharmaceutical composition comprising at least one selected from the group consisting of: phosphate of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one, and crystalline form of phosphate of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one.

[0119] This pharmaceutical composition may include commonly used pharmaceutically acceptable carriers. The carrier is a carrier typically used in this formulation and includes, but is not limited to, lactose, dextran, sucrose, sorbitol, mannitol, starch, gum arabic, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylparaben, propylparaben, talc, magnesium stearate, mineral oil, etc. In addition to the above components, the pharmaceutical composition may further include lubricants, humectants, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, etc.

[0120] The pharmaceutical composition can be administered orally or parenterally, including intravenous, intramuscular, intraperitoneal, subcutaneous, and percutaneous administration.

[0121] In this case, the pharmaceutical composition can be administered at a therapeutically effective dose, for example, an effective dose of about 0.001 mg / kg to about 100 mg / kg per day. The dose can be varied depending on the method of formulation, administration method, age, weight, sexually transmitted disease status, food, administration time, route of administration, patient excretion rate, or response sensitivity.

[0122] The pharmaceutical compositions of this disclosure can be formulated into preparations using pharmaceutically acceptable carriers according to methods readily practiced by those skilled in the art to which this disclosure pertains, such that the compositions can be prepared in unit dose form or by insertion into multi-dose containers. In this case, the preparations can be used without limitation, provided that the preparations are in a form suitable for pharmaceutical preparations, including oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and sprays; topical preparations such as ointments and creams; suppositories; sterile injections, etc. The prepared product may further contain a dispersant or stabilizer.

[0123] [Beneficial Effects] The phosphate of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one and its crystalline form according to this disclosure have lower hygroscopicity and improved stability and solubility compared to the free base, and are therefore suitable for pharmaceutical use. Furthermore, the method for preparing this phosphate or crystalline form has the advantages of large-scale production and improved safety of the preparation process by using reactants that are safer than those used in conventional preparation methods.

[0124] Figure 1 shows the NMR measurement results of the phosphate of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one prepared in Example 1.

[0125] Figure 2 shows the X-ray powder diffraction pattern of the phosphate of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one prepared in Example 1.

[0126] Figure 3 shows the results of differential scanning calorimetry analysis of the phosphate of 1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one prepared in Example 1.

[0127] Figure 4 shows the results of thermogravimetric analysis of the phosphate of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one prepared in Example 1. Detailed Description

[0128] Hereinafter, the present disclosure will be described in more detail with reference to the examples. However, the following examples are for illustrative purposes only, and the scope of the present disclosure is not intended to be limited by the following examples. Furthermore, in the following examples, “volume” can be understood as the ratio of the volume to the weight of the starting material in each step, “parts by weight” can be understood as the weight ratio of the starting material relative to each step of the specification (page 16 / 21, CN 122319150 A), and “eq” can be understood as the equivalent amount of each material.

[0129] Preparation Example: Preparation of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazole-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one (the compound represented by Formula 1)

[0130] Step 1) Preparation of Compounds 1-3 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidinium (100.00 g, 1 eq) as Compound 1-1 and (3S,4R)-4-fluoro-3-hydroxypiperidin-1-carboxylic acid tert-butyl ester (122.45 g, 1.05 eq) as Compound 1-2 were dissolved in 1000.0 mL (10 volumes) of 1,4-dioxane and 10.0 In a mixture of 0.1 mL (volume) of purified water, potassium tert-butoxide (179.05 g, 3 eq) was added, and the mixture was stirred at 48 to 52 °C for 5 hours to complete the reaction.

[0131] Then, 1000.0 mL (10 volumes) of ethyl acetate and 500.0 mL (5 volumes) of purified water were added, and the mixture was stirred for at least 30 minutes, allowed to stand for at least 30 minutes, and then separated into layers. The aqueous layer (lower layer) was discarded. 500.0 mL (5 volumes) of purified water was added to the remaining organic layer, and the mixture was stirred for at least 30 minutes, allowed to stand for at least 30 minutes, and then separated into layers. The aqueous layer (lower layer) was discarded. 500.0 mL (5 volumes) of purified water was added to the remaining organic layer, and the mixture was stirred for at least 30 minutes, allowed to stand for at least 30 minutes, and then separated into layers. The aqueous layer (lower layer) was discarded. The remaining organic layer was concentrated under vacuum at an external temperature of 50°C or lower, 200.0 mL (2 volumes) of 1,4-dioxane was added, and the mixture was concentrated azeotropically at an external temperature of 50°C or lower.

[0132] 200.0 mL (2 volumes) of 1,4-dioxane was added, and the internal temperature was raised to 40–50 °C to completely dissolve the mixture. 400.0 mL (4 volumes) of purified water was added and the mixture was stirred at room temperature for at least 1 hour. Additionally, 600.0 mL (6 volumes) of purified water was added and the mixture was stirred for at least one hour. The resulting mixture was filtered under reduced pressure using a filter and washed with 500.0 mL (5 volumes) of purified water. It was then vacuum dried at an external temperature of 50 °C for 12 hours to obtain (3S,4R)-3-((6-chloro-1H-indol-4-yl)oxy)-4-fluoropiperidine-1-carboxylic acid tert-butyl ester (181.4 g, yield: 92.0%) as compounds 1–3.

[0133] 1H NMR (500 MHz, CD3OD): δ 7.206 (s, 1H), 6.552 (s, 1H), 5.461 (s, 1H), 5.093-4.997 (d, 1H), 3.908-3.793 (d, 2H) , 3.559 (s, 2H) , 2.210 (s, 1H) , 1.926 (s, 1H) , 1.287(s, 9H).

[0134] Step 2) Preparation of Compounds 1-5: Compounds 1-3 (181.40 g, 1 eq) obtained in Step 1, 2-di-tert-butylphosphino-2',4',6'-triisopropylbiphenyl (8.31 g, 0.04 eq), tris(dibenzylacetone)dipalladium(O) (8.96 g, 0.02 eq) and potassium tert-butoxide (164.73 g, 3 eq) were added to 907.2 mL (5 volumes) of sec-butanol and stirred at room temperature. Then, 1-ethyl-1H-pyrazole-4-amine (81.58 g, 1.5 eq) as Compound 1-4 was added, followed by 181.4 mL (1 volume) of sec-butanol, while washing the reactor walls and injection line to ensure that all remaining reagents and raw materials were used in the reaction. The resulting mixture was stirred at an internal temperature of 88 to 92°C for 2 hours to complete the reaction.

[0135] Then, 907.2 mL (5 volumes) of purified water and 907.2 mL (5 volumes) of ethyl acetate were added, the mixture was filtered at an internal temperature of 50°C, and washed with 907.2 mL (5 volumes) of ethyl acetate. 907.2 mL (5 volumes) of purified water was added to the filtrate again, the mixture was stirred for at least 30 minutes, allowed to stand for at least 30 minutes, and then the layers were separated. The aqueous layer (lower layer) was discarded.Add 907.2 mL (5 volumes) of purified water to the remaining organic layer, stir for at least 30 minutes, let stand for at least 30 minutes, then separate the layers and discard the aqueous layer (lower layer). Add 544.3 mL (3 volumes) of 25 wt.% sodium chloride aqueous solution to the remaining organic layer, stir for at least 30 minutes, let stand for at least 30 minutes, then separate the layers and discard the aqueous layer (lower layer). Filter the solution and wash with 907.2 mL (5 volumes) of ethyl acetate. Concentrate the filtrate under vacuum at an external temperature of 60°C or lower, then add 544.3 mL (3 volumes) of ethyl acetate. The mixture was then azeotropically concentrated at an external temperature of 60°C or lower to obtain (3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidine-1-carboxylic acid tert-butyl ester (217.9 g, yield: 100.0%) as compounds 1-5. The obtained compounds were used in the next step without purification.

[0136] Step 3) Preparation of compounds 1-6 The concentrated residue (217.9 g, 1 equivalent) of compounds 1-5 obtained in step 2 was added to and dissolved in 1090.0 mL (6 volumes) of dichloromethane. The solution was cooled to 0 to 5°C and 414.2 mL (2.28 volumes) of concentrated hydrochloric acid was slowly added so that the internal temperature did not exceed 5°C. The mixture was then stirred at 0 to 5°C for 4 hours to complete the reaction.

[0137] Then, 1090.0 mL (6 volumes) of dichloromethane and 1090.0 mL (6 volumes) of purified water were added, and the mixture was stirred for at least 30 minutes, allowed to stand for at least 30 minutes, and then separated into layers. The organic layer (lower layer) was discarded. 1090.0 mL (6 volumes) of dichloromethane was added to the remaining aqueous layer, and the mixture was stirred for 30 minutes or longer, allowed to stand for at least 30 minutes, and then separated into layers. The organic layer (lower layer) was discarded. The mixture was filtered, washed with 1090.0 mL (6 volumes) of purified water, 2179.9 mL (12 volumes) of ethyl acetate was added, and the mixture was cooled to 0 to 5°C. Then, about 1300.0 mL (7.17 volumes) of 8N sodium hydroxide solution was added to adjust the pH to 9 to 11, allowed to stand for at least 30 minutes, and then separated into layers. The aqueous layer (lower layer) was discarded. In addition, add 1090.0 mL (6 volumes) of purified water and stir the mixture for at least 30 minutes, let it stand for more than 30 minutes, and then separate the layers, discarding the water layer (lower layer). Then, concentrate under vacuum at an external temperature of 50°C or lower, add 654.0 mL (3.6 volumes) of methyl isobutyl ketone, and concentrate the mixture azeotropically.

[0138] In addition, 1090.0 mL (6 volumes) of methyl isobutyl ketone was added, the mixture was refluxed and stirred for at least 1 hour, and then the internal temperature was cooled to 20 to 25 °C. 2179.9 mL (12 volumes) of n-heptane was slowly added and stirred for 2 hours. It was filtered and washed with 1090.0 mL (6 volumes) of n-heptane. The washed filtrate was vacuum dried at an external temperature of 50 °C or lower for 12 hours to obtain 126.75 g (2-step in-situ yield: 75.0%) of N-(1-ethyl-1H-pyrazole-4-yl)-4-(((3S,4R)-4-fluoropiperidin-3-yl)oxy)-7H-pyrrolo[2,3-d]pyrimidine-2-amine as compounds 1-6.

[0139] 1H NMR (500 MHz, CD3OD): δ 8.902 (s, 1H), 7.906 (s, 1H), 7.528 (s, 1H), 6.932 (s, 1H), 6.277 (s, 1H), 5.375‑5.330 (d , 1H) , 5.166‑5.066 (d , 1H) , 4.104‑4.061 (d , 2H) , 3.011‑3.002 (d , 2H) , 2.826‑2.664 (dd , 2H) , 2.006‑1.776 (m, 2H) , 1.370 (s, 3H).

[0140] Step 4) Preparation of Compound 1 Compounds 1-6 obtained in Step 3 (126.75 g, 1 eq, 1 part by weight) and sodium bicarbonate (61.66 g, 2 eq) were added to a mixture of 760.5 mL (6 volumes) of tetrahydrofuran and 316.9 mL (2.5 volumes) of purified water, then cooled to 0 to 5 °C and stirred for 1 hour. Acryloyl chloride (6.54 g, 1.1 eq) as Compounds 1-7 was dissolved in 190.1 mL (1.5 volumes) of tetrahydrofuran and added slowly at no more than 5 °C. After the addition was complete, the mixture was stirred at 0 to 5 °C for 2 hours to complete the reaction.

[0141] Then, 1267.5 mL (10 volumes) of purified water and 1267.5 mL (10 volumes) of ethyl acetate were added, the mixture was stirred for at least 30 minutes, allowed to stand for at least 30 minutes, and then separated into layers. The aqueous layer (lower layer) was discarded. It was filtered and washed with 380.3 mL (3 volumes) of ethyl acetate. The filtrate was concentrated under vacuum at an external temperature of 50°C or lower, and then 380.3 mL (3 volumes) of ethanol was added, and the mixture was concentrated under vacuum at an external temperature of 60°C or lower.

[0142] In addition, 316.9 mL (2.5 volumes) of ethanol was added, and the mixture was stirred at 20 to 25°C to dissolve it. 1.27 g (0.01 parts by weight) of compound 1 was added as a seed at 20 to 25°C, and the mixture was stirred for 2 hours. When precipitation had fully occurred, 63.4 mL (0.5 volumes) of ethanol was added, the fluidity was checked, and the mixture was stirred for 2 hours. Then, 1140.7 mL (9 volumes) of n-heptane was added, and the mixture was stirred for 2 hours. The crystalline liquid was filtered and washed with 253.5 mL (2 volumes) of n-heptane. After washing, the filtrate was placed in a dryer and vacuum dried at an external temperature of 50°C or lower for 10 hours to obtain 114.34 g (yield: 78%) of 1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)propyl-2-en-1-one as compound 1.

[0143] H NMR (500 MHz, CD3OD): δ 7.678 (s, 1H), 7.543-7.491 (d, 1H), 6.612-6.424 (m, 2H), 6.320-5.523 (m, 3H), 5.360-5.241 (m, 1H) , 5.185‑5.007 (m, 1H) , 4.709‑3.400 (m, 6H) , 2.192‑1.839 (m, 2H) , 1.358‑1.303 (m, 3H).

[0144] Example 1: Preparation of phosphate of 1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one

[0145] 100.0 mL (1 eq) of ethanol was added to 10-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one (10.0 g, 1 eq) prepared in Preparation Example 1, and dissolved by heating to an external temperature of 60 to 65°C. Foreign material was filtered and transferred using a housing filter (0.45 / 0.22 μm). The residue in the reactor was then washed with 20 mL (2 volumes) of ethanol, followed by further transfer using a housing filter (0.45 / 0.22 μm). The internal temperature was then raised to 60–65 °C and the mixture was stirred.

[0146] Phosphoric acid (4.8 g, 2 eq) was added to the reactor and stirred for 1 hour, then concentrated at an external temperature of 50 to 55°C. 30 mL of ethanol was added and stirred for 2 hours, followed by the addition of 100 mL of ethyl acetate and stirring at room temperature (20–25°C) for at least 2 hours. The reaction solution was cooled to -5 to 5°C, stirred for at least 1 hour, filtered, and washed with 30.0 mL (3 volumes) of ethanol cooled to -5 to 5°C. The obtained filtrate was placed in a dryer and vacuum dried at an external temperature of 55°C or lower to obtain 11.9 g (yield: 98%) of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one phosphate. The NMR results of the obtained 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one phosphate are shown in Figure 1. The phosphate of 1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one was obtained in crystalline form.

[0147] 1H NMR (500 MHz, DMSO-d6) δ 7.89 (s, 1H), 7.52-7.48 (m, 1H), 6.93-6.50 (m, 2H), 6.29-5.45 (m, 4H), 5.33-5.13 (m, 1H), 4.10-3.42 (m, 6H), 2.28-1.85 (m, 2H), 1.37-1.32 (m, 3H).

[0148] Experimental Example 1 (1) X-ray powder diffraction pattern analysis of phosphate The phosphate of Example 1 was analyzed by X-ray powder diffraction, and the results are shown in Figure 2. At this point, a PANalytical X'pert 3 powder X-ray diffractometer (Malvern Panalytical) was used to perform X-ray powder diffraction analysis by providing CuK radiation (λ = 1.54056 Å) to the copper cathode pair (45 kV / 40 mA) as the incident radiation. The step width was 0.02°, the measurement range was 4–50°, and the scan rate was 0.164129° / second.

[0149] Referring to FIG2, it can be confirmed that in the X-ray powder diffraction pattern irradiated by Cu light source, the phosphate of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one prepared in Example 1 has peaks at diffraction angles (2θ±0.2°) of 3.9°, 7.8°, 8.5°, 9.2°, 10.0°, 10.2°, 12.8°, 14.4°, 15.8°, 16.0°, 20.8°, 21.2°, 21.6°, 22.3° and 25.5°.

[0150] (2) Differential scanning calorimetry and thermogravimetric analysis of phosphates The phosphates of Example 1 were analyzed by differential scanning calorimetry, and the results are shown in Figure 3. At this time, differential scanning calorimetry analysis was performed using a DSC Q2000 (obtained from TA Instruments). The sample was heated at a rate of 10°C / min from 30°C to 300°C, and 2 to 5 mg of the product was placed in rolled aluminum capsules and analyzed.

[0151] Referring to FIG3, in differential scanning calorimetry analysis, the phosphate of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one prepared in Example 2 has an endothermic onset temperature of 106.52±1.0℃ and shows a maximum endothermic peak at an endothermic temperature of 123.8±1.0℃.

[0152] (3) Comparison of the physical properties of the free base of the preparation example and the phosphate of the example The physical properties of the free base (compound 1) obtained in the preparation example and the phosphate obtained in Example 1 were measured as follows.

[0153] 1) Melting point: measured using an MP70 obtained from Mettler Toledo. The sample was collected via a capillary tube and then allowed to fall freely using a specific glass rod. This process was repeated several times to ensure there were no empty spaces in the capillary tube. Then, starting from 168°C, the temperature was increased by 1°C per minute to measure the transmittance and confirm the melting point. The measurement results are shown in Table 2 below.

[0154] 2) Thermogravimetric analysis: Measurements were performed using a TGA2 from Mettler Toledo. 50 mg of sample was placed in an Al2O3 dish, and the temperature was increased from 30.0°C at a rate of 10.00°C per minute to confirm the weight change up to 600.0°C. The specific thermogravimetric analysis results are shown in Figure 4.

[0155] 3) Hygroscopicity analysis (DVS hygroscopicity): Measurements were performed using a DVS Adventure from Surface Measurement Systems.Hygroscopicity was confirmed by exposing the sample to 0–95% RH at 25°C using DVS. Hygroscopicity was categorized as non-hygroscopic (0–0.12%), slightly hygroscopic (0.2–2%), moderately hygroscopic (2.0–15.0%), and highly hygroscopic (>15.0%), depending on the degree of moisture absorption. The measurement results are shown in Table 2 below.

[0156] 4) Water solubility: Measured by HPLC from Waters. The sample was supersaturated with water at 23–26°C, stirred for at least 18 hours, and then allowed to stand for at least 18 hours. The supernatant extracted using a centrifuge was filtered through a 0.45 μm filter. The HPLC area of ​​the filtrate was measured to confirm solubility. The measurement results are shown in Table 2 below.

[0157] 5) Stability: Purity was measured after 2 weeks under accelerated testing at 40±2℃ / 75±5% relative humidity. Approximately 1 mg of the phosphate solid obtained in Example 1 was dissolved in 1 ml of 100% methanol, and then 700 μl of acetonitrile was added to 300 μl of this solution for dilution. Purity was measured by HPLC. The measurement results are shown in Table 2 below.

[0158] The HLPC measurement conditions in 4) and 5) above are as follows.

[0159] - Detector: UV spectrophotometer (measurement wavelength: 230 nm) - Diluent: 100% methanol - Sample temperature: 15℃ - Injection volume: 15 μl - Column: X Bridge C18 3.0 * 150 mm, 3.5 µm - Column temperature: 30℃ - Analysis time: 40 min - Flow rate: 0.6 ml / min - Mode: Gradient - Mobile phase A: 20 mM ammonium acetate - Mobile phase B: 100% acetonitrile - Mobile phase A and mobile phase B are controlled according to the concentration gradient shown in Table 1 below.

[0160] [Table 1]

[0161] [Table 2] Specification 21 / 21 Page 27 CN 122319150 A Figure 1 Specification Drawing 1 / 4 Page 28 CN 122319150 A Figure 2 Specification Drawing 2 / 4 Page 29 CN 122319150 A Figure 3 Specification Drawing 3 / 4 Page 30 CN 122319150 A Figure 4 Specification Drawing 4 / 4 Page 31 CN 122319150 A.

Claims

1. 1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one phosphate.

2. The phosphate of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one according to claim 1, in, In the X-ray powder diffraction pattern irradiated by a Cu light source, the phosphate has three or more peaks selected from the group consisting of: 3.9°, 7.8°, 8.5°, 9.2°, 10.0°, 10.2°, 12.8°, 14.4°, 15.8°, 16.0°, 20.8°, 21.2°, 21.6°, 22.3°, and 25.5° with diffraction angles (2θ ± 0.2°).

3. The phosphate of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one according to claim 1, in, In differential scanning calorimetry analysis, the phosphate has an endothermic onset temperature of 106.52±1.0℃ and shows a maximum endothermic peak at an endothermic temperature of 123.8±1.0℃.

4. A method for preparing a phosphate of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one, the method comprising: (Step 1) React the compound represented by the following chemical formula 1-1 with the compound represented by the following chemical formula 1-2 in the presence of a base to prepare the compound represented by the following chemical formula 1-3; (Step 2) React the compounds represented by the following chemical formulas 1-3 with the compounds represented by the following chemical formulas 1-4 in the presence of a palladium catalyst and a base to prepare the compounds represented by the following chemical formulas 1-5; (Step 3) React the compounds represented by the following chemical formulas 1-5 with an acid to prepare the compounds represented by the following chemical formulas 1-6; (Step 4) React the compounds represented by the following chemical formulas 1-6 with the compounds represented by the following chemical formulas 1-7 in the presence of a base to prepare the compound represented by the following chemical formula 1; and (Step 5) React the compound represented by Chemical Formula 1 with phosphoric acid to prepare a phosphate of the compound represented by Chemical Formula 1. Wherein, at least one of steps 1 to 4 further includes a crystallization step: [Chemical Formula 1] [Chemical Formula 1-1] [Chemical Formula 1-2] [Chemical Formulas 1-3] [Chemical Formulas 1-4] [Chemical Formulas 1-5] [Chemical Formulas 1-6] [Chemical Formulas 1-7] Among them, in chemical formulas 1-1 to 1-7, P1 refers to the protecting group.

5. The preparation method according to claim 4, in, In step 1, the compound represented by chemical formula 1-2 is used in amounts ranging from 0.1 to 10 equivalents, based on 1 equivalent of the compound represented by chemical formula 1-1.

6. The preparation method according to claim 4, in, In step 1, the base is at least one selected from the group consisting of: potassium tert-butoxide, sodium tert-butoxide, potassium methoxide, sodium methoxide, potassium tert-pentoxide, sodium tert-pentoxide, triethylamine, diisopropylethylamine, sodium hydroxide, potassium hydroxide, lithium hydroxide, potassium carbonate, calcium carbonate, sodium carbonate, potassium bicarbonate, sodium bicarbonate, and cesium carbonate.

7. The preparation method according to claim 4, in, In step 1, the base is used in an amount of 0.1 to 10 equivalents based on 1 equivalent of the compound represented by chemical formula 1-1.

8. The preparation method according to claim 4, in, In step 1, the reaction is carried out in one or more organic solvents selected from the group consisting of: tetrahydrofuran (THF), 1,4-dioxane, methanol, ethanol, isopropanol, 1-butanol, 2-butanol, acetone, methyl ethyl ketone, ethyl acetate, methyl tert-butyl ether, acetonitrile, toluene, heptane, 3-methyltetrahydrofuran, dichloromethane, methyl isobutyl ketone, dimethylformamide (DMF), dimethylacetamide (DMAC), and dimethyl sulfoxide (DMSO).

9. The preparation method according to claim 8, in, In step 1, the reaction is carried out at 30 to 60°C.

10. The preparation method according to claim 4, in, After the compound represented by chemical formula 1-1 reacts with the compound represented by chemical formula 1-2 in the presence of a base, step 1 further includes the step of crystallizing the reaction product.

11. The preparation method according to claim 4, in, In step 2, compounds represented by chemical formulas 1-3 are used in amounts ranging from 0.1 to 10 equivalents, based on 1 equivalent of the compounds represented by chemical formulas 1-3.

12. The preparation method according to claim 4, in, In step 2, the palladium catalyst is at least one selected from the group consisting of: tris(dibenzylideneacetone)palladium(0), tetra(triphenylphosphine)palladium(0), bis[tris(2-methylphenyl)phosphine)]palladium, palladium acetate(II), 1,1-(bis(diphenylphosphine)ferrocene)palladium(II) chloride, and palladium(II) chloride.

13. The preparation method according to claim 4, in, In step 2, the base is at least one selected from the group consisting of: potassium tert-butoxide, sodium tert-butoxide, potassium methoxide, sodium methoxide, potassium tert-pentoxide, sodium tert-pentoxide, triethylamine, diisopropylethylamine, sodium hydroxide, potassium hydroxide, lithium hydroxide, potassium carbonate, calcium carbonate, sodium carbonate, potassium bicarbonate, sodium bicarbonate, and cesium carbonate.

14. The preparation method according to claim 4, in, In step 2, the reaction is carried out in one or more organic solvents selected from the group consisting of: tetrahydrofuran (THF), 1,4-dioxane, sec-butanol, methanol, ethanol, isopropanol, 1-butanol, 2-butanol, tert-butanol, acetone, methyl ethyl ketone, ethyl acetate, methyl tert-butyl ether, acetonitrile, toluene, xylene, heptane, 3-methyltetrahydrofuran, dichloromethane, methyl isobutyl ketone, dimethylformamide (DMF), dimethylacetamide (DMAC), and dimethyl sulfoxide (DMSO).

15. The preparation method according to claim 4, in, The reaction in step 2 is carried out at 80 to 100°C.

16. The preparation method according to claim 4, in, In step 3, the acid is at least one selected from the group consisting of: hydrochloric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, bromic acid, sulfuric acid, nitric acid, and iodic acid.

17. The preparation method according to claim 4, in, In step 3, the reaction is carried out in one or more organic solvents selected from the group consisting of: ethyl acetate, dichloromethane, butyl acetate, chloroform, methanol, ethanol, isopropanol, 1-butanol, 2-butanol, acetone, methyl ethyl ketone, methyl tert-butyl ether, acetonitrile, toluene, heptane, tetrahydrofuran, 3-methyltetrahydrofuran, 1,4-dioxane, methyl isobutyl ketone, dimethylformamide (DMF), dimethylacetamide (DMAC), and dimethyl sulfoxide (DMSO).

18. The preparation method according to claim 4, in, The reaction in step 3 is carried out at a temperature between 0°C and 50°C.

19. The preparation method according to claim 4, in, After reacting the compounds represented by chemical formulas 1-5 with an acid, step 3 further includes the step of crystallizing the reaction product.

20. The preparation method according to claim 4, in, In step 4, compounds represented by chemical formulas 1-6 are used in amounts ranging from 0.1 to 10 equivalents, based on 1 equivalent of the compounds represented by chemical formulas 1-6.

21. The preparation method according to claim 4, in, In step 4, the alkali is at least one selected from the group consisting of: potassium carbonate, sodium hydroxide, lithium hydroxide, potassium hydroxide, triethylamine, diisopropylamine, diisopropylethylamine, sodium bicarbonate, potassium bicarbonate, cesium carbonate, sodium carbonate, sodium methoxide, and potassium butyrate.

22. The preparation method according to claim 4, in, The reaction in step 4 is carried out at a temperature between -10°C and 50°C.

23. The preparation method according to claim 4, in, After reacting the compounds represented by chemical formulas 1-6 with the compounds represented by chemical formulas 1-7 in the presence of a base, step 4 further includes the step of crystallizing the reaction products.

24. The preparation method according to claim 4, in, In step 5, the reaction is carried out in one or more organic solvents selected from the group consisting of: 2-butanol, acetone, methyl ethyl ketone, ethyl acetate, methyl tert-butyl ether, acetonitrile, toluene, heptane, tetrahydrofuran, 3-methyltetrahydrofuran, 1,4-dioxane, dichloromethane, methyl isobutyl ketone, dimethylformamide (DMF), dimethylacetamide (DMAC), and dimethyl sulfoxide (DMSO).

25. Crystalline form of phosphate of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one.

26. The crystalline form of the phosphate of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one according to claim 25, In the X-ray powder diffraction pattern, the crystalline form has three or more peaks selected from the group consisting of: 3.9°, 7.8°, 8.5°, 9.2°, 10.0°, 10.2°, 12.8°, 14.4°, 15.8°, 16.0°, 20.8°, 21.2°, 21.6°, 22.3°, and 25.5° with diffraction angles (2θ ± 0.2°).

27. The crystalline form of the phosphate of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one according to claim 25, In differential scanning calorimetry analysis, the crystalline form has an endothermic onset temperature of 106.52±1.0℃ and shows a maximum endothermic peak at an endothermic temperature of 123.8±1.0℃.

28. A pharmaceutical composition for the prevention or treatment of inflammatory diseases, autoimmune diseases, proliferative diseases, hyperproliferative diseases, immune-mediated diseases, cancers, or tumors, the pharmaceutical composition comprising at least one selected from the group consisting of: 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one phosphate, and the crystalline form of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one phosphate.

29. A method for preparing phosphate of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one, The method includes compounds represented by the following chemical formulas 1-5 as intermediates: [Chemical Formulas 1-5] Among them, in chemical formulas 1-5, P1 refers to the protecting group.

30. The preparation method according to claim 29, in, P1 is tert-butoxycarbonyl (Boc).

31. Compounds represented by the following chemical formulas 1-5, [Chemical Formulas 1-5] in, In chemical formulas 1-5, P1 refers to the protecting group.

32. The compound according to claim 31, in, P1 is tert-butoxycarbonyl (Boc).